In this research, a medicated antifungal nail polish containing Terbinafine and Clobetasol propionate was developed. Long-term, sustained release of Terbinafine and Clobetasol propionate was investigated in the hopes of lowering the frequency of dosing. Toenail fungus, also known as onychomycosis, is quite common. Infection with dermatophytes, Candida, or non-dermatophytic molds can lead to onychomycosis. In terms of non-volatile content, drug release, drug content estimate, and inhibitory zone, the optimum formulation was a nail lacquer comprising 1-2 percent Terbinafine and Clobetasol propionate, as well as 3 percent ethyl cellulose. Up to 48 hours after administration, 98.12% of the drug was still active. FTIR tests confirmed that the drug and excipient were safe to use together. It was expected that this would improve clinical efficacy and patient compliance. The nail polish formulations were created by simply combining the necessary ingredients together, and then evaluated for non-volatile content, flowability, drug diffusion studies, and an estimate of the drug content. The selected optimized formulation, F4, showed no significant change in initial attributes throughout a month-long accelerated stability analysis performed at 40-20°C in accordance with ICH norms. The development and deployment of these systems pose no known dangers. Antifungal nail lacquer is a potential novel dosage form in the healthcare and pharmaceutical industries.